Organization (Hospital)
Hospital Sírio-Libanês
ClinicalTrials.gov lists Hospital Sírio-Libanês as lead sponsor of 44 trials. It has 9 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Hospital Sírio-Libanês: 44 lead-sponsored trials and 1 legal-entity registration.
Disease areas (59)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 6 |
| Carcinoma, Hepatocellular | 4 |
| Liver Neoplasms | 4 |
| Cleft Lip | 3 |
| Cross Infection | 3 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 11 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 18 years.
Prediction, not a registry value: median of 27 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; 2 of 6 predicted trials reach the 36-month horizon; registered median of 12 months across 25 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Biperiden | Brain Injuries | Phase 3 | 1 |
| Biperiden | Epilepsy, Post-Traumatic | Phase 3 | 1 |
| Biperiden | Epilepsy | Phase 3 | 1 |
| Vitamin C | Sepsis | Phase 3 | 1 |
| Vitamin C | Inflammation | Phase 3 | 1 |
Showing 5 of 9 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Anticoagulant Oral | 1 |
| Carvedilol | 1 |
| Biperiden | 1 |
| DEXAMETHASONE | 1 |
| Vitamin C | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 88% hit target (n=8) | 56% on time (n=9) |
Journals published in (106)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of respiratory and critical care medicine | 6 |
| Critical care medicine | 6 |
| Intensive care medicine | 5 |
| PloS one | 5 |
| The Cochrane database of systematic reviews | 5 |
Showing 5 of 106 journals.
Organization relationships (37)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Renji Hospital | Co sponsors trial with | 1 |
| Technische Universität Dresden | Co sponsors trial with | 1 |
| Hospital Israelita Albert Einstein | Co sponsors trial with | 1 |
| Health New Zealand | Co sponsors trial with | 1 |
Showing 5 of 37 relationships.
Latest dated events (63)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 63 events.
Biomarker capability evidence (74)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial collaborator | Named in trial inclusion criteria |
| BTBD8 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 74 evidence rows.
Biomarkers this organization publishes on (196)
Shown in this order: most publications first.
Showing 5 of 196 biomarkers.
On Scientist.com
Hospital Sírio-Libanês is listed as a research supplier in the Scientist.com network.
Service areas
Hospital Sírio-Libanês focuses on research and education.
- Website
- www.hospitalsiriolibanes.org.br
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Hospital Sírio-Libanês on Scientist.com
For prices, more details, or to contact Hospital Sírio-Libanês, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.